QGEN - Qiagen Debt to Book Capitalization Ratio

Corporate company logo of Qiagen (QGEN)

Qiagen N.V. creates a closed-loop sample preparation cycle where equipment locks laboratories into using its own consumables. Revenues are based on the supply of tests to biotech giants and clinics. Strict FDA regulations serve as a business moat. Capital structure trend: the debt-to-book capitalization ratio reflects the dynamics of borrowed funds, with the parameter reaching 0.46.

QGEN - Qiagen Corp Debts to Net Assets over the range 07/04/2022 - 10/28/2026
Finished products of Qiagen NV

To identify fundamental benchmarks in the financial statements of Qiagen N.V. (QGEN), assessing the stability of the capital structure is critical. By analyzing the dynamic debt-to-book capitalization ratio, an investor can determine the proportion of total liabilities to asset value, making it possible to identify credit overheating that could offset the high margins of the molecular diagnostics consumables business and drive down the share price.

Competitors of Qiagen N.V. (QGEN)

Debts to Book Capitalization TEM (Tempus AI Inc)|ionispharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio RGEN|RNA - Debt to Net Assets|CRISPR Therapeutics Corp - Debts to Book Capitalization|GeneDx Corp (WGS) - Debts to Net Assets|RARE (Ultragenyx Pharmaceutical) - Debts to Book Capitalization|Debts to Book Capitalization beamtx.com|SRPT: Debts to Book Capitalization|Debt to Net Assets Twist Bioscience Inc (TWST)|TXG: Debts to Book Capitalization|Intellia Corp - Debts to Book Value|Stoke Therapeutics (STOK) - Debt to Book Capitalization Ratio|biolifesolutions.com (BLFS) - Debt to Book Value Ratio|Debt to Book Value Wave Life Sciences Ltd. WVE|MAZE (Maze Therapeutics, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Sionna Pharma (SION)|Debt to Book Value Ratio Prime Medicine Bio (PRME)|TSHA (Taysha Gene Therapies) - Debt to Book Value|Debts to Net Assets uniqure.com QURE|Debt to Book Value MeiraGTx MGTX|RGNX - Debt to Book Capitalization Ratio|Debt to Book Value SLDB (Solid Bio)|OCGN: Debts to Net Assets|Debt to Book Capitalization Ratio PACB (Pacific Biosciences)|benitec.com (BNTC) - Debt to Net Assets|Design Therapeutics, Inc. - Debts to Book Capitalization|Debt to Net Assets Rocket Pharma|4D Molecular Therapeutics Inc - Debts to Book Capitalization|Debts to Book Value LXEO (lexeotx.com)|KRRO - Debt to Book Capitalization Ratio|Debt to Book Value Ratio editasmedicine.com EDIT|Silence Therapeutics plc (SLN) - Debts to Book Capitalization|PRQR: Debt to Book Value Ratio|Debt to Book Capitalization Ratio codexis.com|Sangamo BioSciences (SGMO) - Debt to Book Value Ratio|NAUT (Nautilus Biotechnology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization MGX|DTIL: Debt to Book Capitalization Ratio|Debt to Net Assets generationbio.com (GBIO)|Debts to Book Capitalization BOLD|Debts to Net Assets Exicure Inc. XCUR|Celsion Corporation - Debts to Book Capitalization|PHIO - Debts to Book Capitalization|Debts to Book Capitalization MBIO (mustangbio.com)|TransCode Therapeutics, Inc. (RNAZ) - Debt to Net Assets|Debts to Book Capitalization BNGO (Bionano Genomics Inc.)|Debts to Book Value APDN|Debt to Book Capitalization Ratio bluebird bio, Inc. BLUE|Debt to Book Value Ratio immunoprecise.com IPA|Debt to Book Value Omega Therapeutics, Inc.|Singular Genomics Systems, Inc. - Debt to Net Assets Ratio|Regulus Therapeutics Inc (RGLS) - Debt to Book Capitalization Ratio|Syros Pharmaceuticals, Inc (SYRS) - Debt to Book Value Ratio|Telesis Bio, Inc. - Debt to Book Value|Debts to Net Assets traconpharma.com|Debt to Book Value Unity Biotechnology, Inc.